ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Genetic pleiotropy differentially linking brain variation to cannabis use and cannabis use disorder.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since cannabis use (CU) has increased substantially worldwide, understanding the neurobiological mechanisms differentiating CU from cannabis use disorder (CUD) has important public health implications. Leveraging genome-wide data available from UK Biobank, International Cannabis Consortium, the Psychiatric Genomics Consortium, and the Million Veteran Program, we characterized the pleiotropy differentially linking brain structural and functional variation to CU and CUD. Specifically, we conducted linkage disequilibrium score regression, local analysis of [co]variant association, and latent causal variable analysis. Distinct patterns of global genetic correlations were observed, where CU was specifically related to default mode network-related functional activity and the functional connectivity between default mode and central executive networks, while CUD was related to functional connectivity linking default mode and salience networks and with white matter microstructure. Latent causal variable analyses suggested partial genetic causality differentially linking the functional connectivity among salience, default mode, and central executive networks to CU and CUD. Local genetic correlation analyses further identified CU and CUD-specific shared genetic architecture with brain variation related to genes involved in neurodevelopment, chromatin regulation, synaptic signaling, and white matter biology. Through gene-set enrichment analyses, we identified pathways related to brain variation converging on inflammatory response and cell activation for CU, and on cellular stress-response and immune regulation for CUD. Applying gene2drug framework, our drug-repurposing analyses identified nine molecular compounds, also including raloxifene (a cannabinoid-receptor 2 inverse agonist) and albendazole (reported to interact with cannabis smoking). Overall, these findings provide new insights into the neurobiological pathways underlying CU and its progression to CUD.
Identifiers
42533056What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.